• Profile
Close

Veverimer vs placebo in patients with metabolic acidosis associated with chronic kidney disease: A multicentre, randomised, double-blind, controlled, phase 3 trial

The Lancet Apr 10, 2019

Wesson DE, et al. - In patients with chronic kidney disease, researchers tested the safety and effectiveness of veverimer [a non-absorbed, counterion-free, polymeric drug] as a treatment for metabolic acidosis. Patients (aged 18–85 years) with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration rate of 20–40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12–20 mmol/L) were eligible participants. During their typical diet, patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks. Both drugs were taken in water with lunch as oral suspensions. According to this multicentre, parallel, randomised, double-blind, placebo-controlled study, veverimer corrected metabolic acidosis effectively and safely. Long-term studies are warranted to evaluate the effects of veverimer on physical functioning and to evaluate other harmful effects of metabolic acidosis including progression of chronic kidney disease and bone health. Diarrhoea, flatulence, nausea, and constipation were the most common treatment-related adverse events.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay